CD80 and neoplasm: In addition, we found that key immune-checkpoint inhibitors and their ligands such as PD1-PDL1 (CD274) and CTLA4-CD80/86 had higher interaction score in tumor than that in normal samples (Fig. 5G), in concordant with our above observation that both CD4 and CD8 T cells were more exhaustive in tumor samples.